Tscan Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $1,051 | $982 | $2,567 | $2,511 |
Gross Profit | 1,051 | 289 | 2,567 | 2,511 |
EBITDA | -28,961 | -27,284 | -21,552 | -34,244 |
EBIT | -29,660 | -27,977 | -22,275 | -35,011 |
Net Income | -30,359 | -28,666 | -22,977 | -35,710 |
Net Change In Cash | 1,051 | 982 | 2,567 | 2,511 |
Free Cash Flow | -28,028 | -24,349 | -32,173 | -33,889 |
Cash | 100,156 | 128,057 | 152,406 | 169,506 |
Basic Shares | 129,948 | 129,913 | 129,862 | 129,835 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $10,325 | $2,816 | $21,049 | $13,535 |
Gross Profit | 7,459 | 2,816 | 21,049 | 13,535 |
EBITDA | -124,131 | -119,738 | -80,098 | -59,908 |
EBIT | -126,997 | -123,846 | -85,459 | -65,045 |
Net Income | -129,766 | -127,499 | -89,218 | -66,221 |
Net Change In Cash | 10,325 | 2,816 | 21,049 | 13,535 |
Cost of Revenue | -41,372 | |||
Free Cash Flow | -139,726 | -114,647 | -64,504 | -70,728 |
Cash | 152,406 | 178,689 | 133,359 | 120,027 |
Basic Shares | 129,862 | 111,990 | 65,599 | 24,048 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.23 |
2026-03-31 | -$0.22 |
2025-12-31 | -$0.18 |
2025-09-30 | -$0.28 |